AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
5.63
-0.14 (-2.43%)
At close: Oct 28, 2025, 4:00 PM EDT
5.62
-0.01 (-0.18%)
Pre-market: Oct 29, 2025, 4:44 AM EDT
AbCellera Biologics Employees
AbCellera Biologics had 596 employees as of December 31, 2024. The number of employees increased by 10 or 1.71% compared to the previous year.
Employees
596
Change (1Y)
10
Growth (1Y)
1.71%
Revenue / Employee
$55,161
Profits / Employee
-$277,961
Market Cap
1.68B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 596 | 10 | 1.71% |
| Dec 31, 2023 | 586 | 91 | 18.38% |
| Dec 31, 2022 | 495 | 109 | 28.24% |
| Dec 31, 2021 | 386 | 180 | 87.38% |
| Dec 31, 2020 | 206 | 99 | 92.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ABCL News
- 21 days ago - AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 - Business Wire
- 22 days ago - AbCellera Biologics: Entering Growth Phase After A Pause - Seeking Alpha
- 4 weeks ago - AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire
- 6 weeks ago - AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer - Business Wire
- 2 months ago - AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 - Business Wire
- 2 months ago - AbCellera to Participate at Upcoming Investor Conferences in September - Business Wire
- 2 months ago - AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - Business Wire